Pharmaceutical Implications of Sex-Related RNA Divergence in Psychiatric Disorders

Alon Simchovitz-Gesher, Hermona Soreq*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

Male–female differences have long been observed in the epidemiology and clinical presentation of psychiatric disorders. Current understanding is based on sex hormones and on transcription patterns governed by the sex chromosomes, and specific sexually dimorphic pathways were only recently identified. However, the underlying molecular mechanisms and pharmaceutical implications remain unclear. We highlight the importance of studying the sex-specific patterns of mental diseases at all levels from genomics to pharmaceutics. In particular, we discuss transcriptional level differences between the sexes in psychiatric disorders and outline the possible impact of such research on future pharmaceutical developments.

Original languageEnglish
Pages (from-to)840-850
Number of pages11
JournalTrends in Pharmacological Sciences
Volume41
Issue number11
DOIs
StatePublished - Nov 2020

Bibliographical note

Publisher Copyright:
© 2020 The Authors

Keywords

  • cholinergic network
  • noncoding RNAs
  • pharmaceutics
  • psychiatric disorders

Fingerprint

Dive into the research topics of 'Pharmaceutical Implications of Sex-Related RNA Divergence in Psychiatric Disorders'. Together they form a unique fingerprint.

Cite this